It provides promising clinical strategies for treatment with HPV18‐positive patients of CIN and ICC through the application of Wnt/β‐catenin signaling pathway inhibitors, which has been applied to phase II clinical trial [29, 39], or in combination with proteasome inhibitors for blocking HPV18‐mediated MAGI3 degradation. The gene discussed is MAGI3; the disease is intrahepatic cholangiocarcinoma.